▶ 調査レポート

臨床試験イメージングのグローバル市場(~2027):サービス、ソフトウェア

• 英文タイトル:Clinical Trial Imaging Market Research Report by Product & Service, Modality, Therapeutic area, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。臨床試験イメージングのグローバル市場(~2027):サービス、ソフトウェア / Clinical Trial Imaging Market Research Report by Product & Service, Modality, Therapeutic area, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2304F212資料のイメージです。• レポートコード:MRC2304F212
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、228ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療機器
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の本調査レポートによると、2021年に968.95百万ドルであった世界の臨床試験イメージング市場規模は2022年に1,035.32百万ドルになり、更に年平均7.02%拡大して2027年までに1,456.34百万ドルに達する見通しです。本書は、臨床試験イメージングの世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品&サービス別(サービス、ソフトウェア)分析、モダリティ別(コンピュータ断層撮影(CT)、心エコー検査、磁気共鳴画像(MRI)、陽電子放出断層撮影(PET)、超音波)分析、治療領域別(CVS、内分泌、免疫、感染症、神経)分析、エンドユーザー別(学術&政府研究機関、バイオテクノロジー企業、受託研究機関、医療機器メーカー、製薬会社)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容をまとめた市場調査レポートです。なお、本書に掲載されている企業情報には、anagram 4 clinical trials、BioClinica Inc.、Biomedical Systems Corporation、Biospective Inc.、BioTelemetry Inc.、Boston Imaging Core Lab LLC.、Calyx Group、Cardiovascular Imaging Technologies LLC.、ICON plc.、Imaging Endpoints LI, LLC、Intrinsic Imaging LLC.などが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の臨床試験イメージング市場規模:製品&サービス別
- サービスの市場規模
- ソフトウェアの市場規模
・世界の臨床試験イメージング市場規模:モダリティ別
- コンピュータ断層撮影(CT)の市場規模
- 心エコー検査の市場規模
- 磁気共鳴画像(MRI)の市場規模
- 陽電子放出断層撮影(PET)の市場規模
- 超音波の市場規模
・世界の臨床試験イメージング市場規模:治療領域別
- CVSにおける市場規模
- 内分泌疾患における市場規模
- 免疫疾患における市場規模
- 感染症における市場規模
- 神経疾患における市場規模
・世界の臨床試験イメージング市場規模:エンドユーザー別
- 学術&政府研究機関における市場規模
- バイオテクノロジー企業における市場規模
- 受託研究機関における市場規模
- 医療機器メーカーにおける市場規模
- 製薬会社における市場規模
・世界の臨床試験イメージング市場規模:地域別
- 南北アメリカの臨床試験イメージング市場規模
アメリカの臨床試験イメージング市場規模
カナダの臨床試験イメージング市場規模
ブラジルの臨床試験イメージング市場規模
...
- アジア太平洋の臨床試験イメージング市場規模
日本の臨床試験イメージング市場規模
中国の臨床試験イメージング市場規模
インドの臨床試験イメージング市場規模
韓国の臨床試験イメージング市場規模
台湾の臨床試験イメージング市場規模
...
- ヨーロッパ/中東/アフリカの臨床試験イメージング市場規模
イギリスの臨床試験イメージング市場規模
ドイツの臨床試験イメージング市場規模
フランスの臨床試験イメージング市場規模
ロシアの臨床試験イメージング市場規模
...
- その他地域の臨床試験イメージング市場規模
・競争状況
・企業情報

The Global Clinical Trial Imaging Market size was estimated at USD 968.95 million in 2021 and expected to reach USD 1,035.32 million in 2022, and is projected to grow at a CAGR 7.02% to reach USD 1,456.34 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Clinical Trial Imaging to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product & Service, the market was studied across Services and Software. The Services is further studied across Operational Imaging Services, Read Analysis Services, System & Technical Support Services, and Trial Design & Consulting Services.

Based on Modality, the market was studied across Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-ray.

Based on Therapeutic area, the market was studied across CVS, Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology.

Based on End-User, the market was studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturer, and Pharmaceutical Companies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Clinical Trial Imaging market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clinical Trial Imaging Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Clinical Trial Imaging Market, including anagram 4 clinical trials, BioClinica Inc., Biomedical Systems Corporation, Biospective Inc., BioTelemetry Inc., Boston Imaging Core Lab LLC., Calyx Group, Cardiovascular Imaging Technologies LLC., ICON plc., Imaging Endpoints LI, LLC, Intrinsic Imaging LLC., IXICO plc., Lyscaut Medical Imaging Company, Medical Metrics Inc., Medpace Holdings, Inc., Micron Inc., Parexel International Corporation, Perspectum Ltd., Pharmtrace klinische Entwicklung GmbH, Prism Clinical Imaging, Inc., ProScan Imaging LLC., Radiant Sage LLC., Resonance Health Ltd., and WorldCare Clinical, LLC.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Clinical Trial Imaging Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Clinical Trial Imaging Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Clinical Trial Imaging Market?
4. What is the competitive strategic window for opportunities in the Global Clinical Trial Imaging Market?
5. What are the technology trends and regulatory frameworks in the Global Clinical Trial Imaging Market?
6. What is the market share of the leading vendors in the Global Clinical Trial Imaging Market?
7. What modes and strategic moves are considered suitable for entering the Global Clinical Trial Imaging Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Significant investments made in drug development programs
5.1.1.2. Significant reduction in the drug development and approval timelines
5.1.1.3. A non-invasive method of study and usability when a biopsy is not possible
5.1.2. Restraints
5.1.2.1. Data security and privacy issues and possibility of misusing the images obtained for studies
5.1.3. Opportunities
5.1.3.1. Development of cloud-based platform simplifying the process of image sharing
5.1.3.2. Integration of artificial intelligence (AI) to minimize errors and maximize efficiency
5.1.4. Challenges
5.1.4.1. High cost associated with the imaging techniques and potential exposure to prohibitive radiation
5.2. Cumulative Impact of COVID-19

6. Clinical Trial Imaging Market, by Product & Service
6.1. Introduction
6.2. Services
6.3.1. Operational Imaging Services
6.3.2. Read Analysis Services
6.3.3. System & Technical Support Services
6.3.4. Trial Design & Consulting Services
6.3. Software

7. Clinical Trial Imaging Market, by Modality
7.1. Introduction
7.2. Computed Tomography
7.3. Echocardiography
7.4. Magnetic Resonance Imaging
7.5. Positron Emission Tomography
7.6. Ultrasound
7.7. X-ray

8. Clinical Trial Imaging Market, by Therapeutic area
8.1. Introduction
8.2. CVS
8.3. Endocrinology
8.4. Immunological Disorder
8.5. Infectious Diseases
8.6. Neurology
8.7. Oncology

9. Clinical Trial Imaging Market, by End-User
9.1. Introduction
9.2. Academic & Government Research Institutes
9.3. Biotechnology Companies
9.4. Contract Research Organizations
9.5. Medical Device Manufacturer
9.6. Pharmaceutical Companies

10. Americas Clinical Trial Imaging Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Clinical Trial Imaging Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Clinical Trial Imaging Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. anagram 4 clinical trials
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. BioClinica Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Biomedical Systems Corporation
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Biospective Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. BioTelemetry Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Boston Imaging Core Lab LLC.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Calyx Group
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Cardiovascular Imaging Technologies LLC.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. ICON plc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Imaging Endpoints LI, LLC
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Intrinsic Imaging LLC.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. IXICO plc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Lyscaut Medical Imaging Company
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Medical Metrics Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Medpace Holdings, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Micron Inc.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Parexel International Corporation
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Perspectum Ltd.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Pharmtrace klinische Entwicklung GmbH
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Prism Clinical Imaging, Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. ProScan Imaging LLC.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Radiant Sage LLC.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Resonance Health Ltd.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. WorldCare Clinical, LLC
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing